Welcome to our dedicated page for Bluejay Diagnostics news (Ticker: BJDX), a resource for investors and traders seeking the latest updates and insights on Bluejay Diagnostics stock.
Bluejay Diagnostics develops rapid, near-patient diagnostic testing for critical care settings through its Symphony™ platform. The company’s lead product candidate, the Symphony™ IL-6 Test, is designed to measure interleukin-6 for sepsis triage, patient monitoring, and risk assessment, with sample-to-result testing described at approximately 20 minutes.
Bluejay news commonly covers SYMON clinical studies, IL-6 biomarker data, conference presentations, manufacturing readiness for Symphony cartridges, antibody production for test components, and regulatory preparation. Company updates also include financing activity, warrant exercises, reverse stock splits, and other capitalization matters. The Symphony System does not yet have U.S. FDA regulatory clearance and requires authorization before it can be marketed as a diagnostic product in the United States.
Bluejay Diagnostics (NASDAQ:BJDX) provided a Q1 2026 corporate update on May 7, 2026 covering progress on its Symphony™ near-patient diagnostic platform.
Key points: SYMON-II enrollment at ~680 of 750 target patients as of May 5, 2026; resolved Symphony cartridge manufacturing issues with Sanyoseiko; maintaining objective to prepare a 510(k) submission after analytical and clinical validation; cash ~$3.7M and Q1 net loss ~$1.9M.
Bluejay Diagnostics (NASDAQ: BJDX) announced enrollment of 624 patients in the pivotal SYMON-II trial testing the Symphony™ IL-6 platform for sepsis triage and monitoring.
The study target is 750 patients; the company expects to complete enrollment within 2–3 months, contingent on site activity and patient flow, and noted inclusion/exclusion criteria have not materially limited enrollment.
Bluejay Diagnostics (NASDAQ: BJDX) announced an abstract acceptance for the 2026 SAEM Annual Meeting, May 18–21, 2026 in Atlanta.
The presentation reports SYMON-I pilot results linking emergency department IL-6 levels to organ dysfunction (SOFA) over the first three hospital days and notes the ongoing SYMON-II validation study.
Bluejay Diagnostics (NASDAQ: BJDX) provided a corporate update outlining 2026 priorities: complete the SYMON™ II IL-6 clinical study, advance FDA regulatory submission planning, and scale manufacturing and supply chain readiness for its Symphony platform. The company reported approximately $5.2M cash, $6.0M stockholders' equity, ~972,000 common shares outstanding, and a $6.8M net loss for FY2025. Bluejay completed a $3.8M warrant-inducement financing and a $4.5M PIPE in 2025, converted prefunded warrants without incremental dilution, and expects to raise at least $20M through end of 2027 to support commercialization and operations.
Bluejay Diagnostics (NASDAQ: BJDX) announced that as of Feb 19, 2026 all prefunded warrants from its Oct 2025 private placement were fully exercised, leaving approximately 972,000 shares of common stock outstanding.
The company reports about 1.5 million cash-exercisable warrants remain, each with a cash exercise price of $7.00 or greater, and reminds investors that Schedule 13G filings may show pre-split share counts after the 1-for-4 reverse split on Jan 29, 2026.
Bluejay Diagnostics (NASDAQ: BJDX) enrolled 545 patients in the SYMON II multicenter IL-6 monitoring study, toward a 750-patient target, and advanced manufacturing readiness into 2026. Key manufacturing milestones include cartridge characterization for U.S. commercial production and antibody supply sufficient for more than 10 million test cartridges.
The company is progressing technology transfer, analytical validation, and fabrication under defined protocols while noting the Symphony System does not yet have FDA clearance and requires authorization before U.S. marketing.
Bluejay Diagnostics (NASDAQ: BJDX) announced a 1-for-4 reverse stock split effective at 12:01 a.m. ET on January 29, 2026. At the effective time every four issued and outstanding shares will be combined into one share, reducing outstanding common stock from approximately 2,834,133 shares to approximately 708,533. The company’s trading symbol BJDX remains unchanged and a new CUSIP 095633608 will be used post-split. Prefunded warrants will be adjusted from 1,055,000 to 263,750. No fractional shares will be issued; holders will receive a cash payment in lieu of fractional shares. Transfer agent Continental Stock Transfer & Trust Company will act as exchange agent and certificate holders will receive instructions. Equity awards and warrants will be proportionally adjusted.
The company noted it does not yet have FDA clearance for its Symphony System; its IL-6 sepsis test is designed for ~20-minute sample-to-result performance.
Bluejay Diagnostics (NASDAQ: BJDX) announced completion of commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6) for its Symphony™ cartridge program on December 29, 2025. The company said both antibody types met internal performance criteria for reactivity and intended diagnostic use based on internal testing.
Bluejay reported production using third-party and proprietary immunogens, plans to use its proprietary immunogen for ongoing development and IP strategy, and estimates current inventory can support production of more than nine million Symphony cartridges, with capability to produce additional antibodies as needed. Symphony remains under development and subject to further validation and regulatory review.
Bluejay Diagnostics (NASDAQ:BJDX) reported Q3 2025 results and highlighted clinical and financing progress.
Key facts: SYMON-II pivotal trial is ~50% enrolled and aims to validate IL-6 predictive performance for 28-day mortality; Symphony sample testing is planned by late 2026 and a potential FDA 510(k) submission is targeted in 2027, subject to financing. The company completed a $4.5M PIPE in October and a $3.85M warrant-inducement in April; cash was $3.08M and stockholders’ equity $3.69M as of Sept 30, 2025. Bluejay amended supply agreements with SanyoSeiko and says Symphony delivers results in ~20 minutes.
Bluejay Diagnostics (NASDAQ: BJDX) announced on October 10, 2025 the closing of a private placement that generated $4.5 million gross proceeds. The offering comprised 2,250,000 shares of common stock (or pre-funded warrants) and accompanying Series F warrants to purchase up to 4,500,000 shares at a purchase price of $2.00 per share and Series F warrant exercise price of $1.75. Series F warrants are exercisable immediately and expire in five and one-half years. Rodman and Renshaw acted as placement agent. The company said net proceeds will fund FDA approval efforts and related clinical studies, R&D, and general working capital. Securities were sold in a Regulation D/private placement with agreed resale registration rights.